Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004079 · ClinicalTrials.gov registry record · Phase 1

Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
46
Enrollment target

NCT00004079: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT00004079 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00004079, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target

Study Summary

Phase I trial to study the effectiveness of sarcosinamide nitrosourea in treating patients who have metastatic or unresectable solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • DRUG SarCNU

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 1999-08
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00004079 record still lists

NCT00004079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).

The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00004079 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00004079 about?

NCT00004079 is a clinical study titled "Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors". Phase I trial to study the effectiveness of sarcosinamide nitrosourea in treating patients who have metastatic or unresectable solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

What is the current status of trial NCT00004079?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 1999-08.

What interventions are being tested in trial NCT00004079?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), SarCNU (DRUG).

Who is sponsoring clinical trial NCT00004079?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00004079's enrollment target sits among peer trials

46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00004079, the US trial registry maintained by the National Library of Medicine. NCT00004079 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.